MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma: a preliminary study.

ABSTRACT:

Background

Multiple myeloma (MM) is a complex hematological malignancy with heterogeneous clinical and pathophysiological backgrounds that influence treatment responses and outcomes. Identifying biomarkers to predict drug response and guide treatment decisions, particularly regarding drug combinations, is essential to improve therapeutic efficacy and patient outcomes. This study explores the role of microRNAs (miRNAs/miRs) derived from bone marrow (BM) and peripheral blood (PB) in responses to treatment and survival outcomes in newly diagnosed MM (ndMM) patients.

Methods

This study included twenty patients with ndMM undergoing first-line treatment with bortezomib, thalidomide, and dexamethasone. The miRNAs were isolated from BM and PB, and their profiles were analyzed using

SUBMITTER: Bergantim R 

PROVIDER: S-EPMC12006192 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature